Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

EnteroMedics May Get Approval, But Will It Get Sales?

Friday was not a good day for EnteroMedics (NASDAQ:ETRM) shareholders. Although it would be a stretch to say that there was a real expectation that this company had a high-potential weight loss solution in its hands (the market cap was about $125 million prior to Friday's news), there were definitely some analysts and investors who thought that the company's VBLOC therapy and Maestro system had potential in treating morbidly obese individuals.

While the company's ReCharge study was a technical failure, there was evidence of efficacy from the device and the safety profile was pretty clean. Even so, convincing the FDA to approve this system may not even be the biggest issue for the company. The bigger issue is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details